Investor Interest in BioNTech Founders’ Next Project Hots Up

Leading venture capital firms from Europe and the USA, family offices operating on behalf of major investor families (German billionaire twins the Strüngmanns) and other billionaires – including Microsoft co-founder Bill Gates – are allegedly taking a keen interest in the next steps taken by the couple who are set to leave the Mainz biotech company at the end of the year. 

BioNTech’s fortunes were transformed from a research-led start-up to a global biotech concern with the development of the first approved mRNA-based vaccine during the Covid-19 pandemic. 

Although still in the conceptual phase, discussions with potential investors are reportedly already underway for the project that will most likely concentrate on next-generation mRNA development. BioNTech will also have a contribution-in-kind stake in the planned company as a result of usage rights related to fundamental MRNA patents.